Hemab Therapeutics
$41.19
2
-$0.03-0.07% Friday 20:00
+$0.00+0%Friday 20:14After hours
Statistics
Day High
41.25
Day Low
41.06
52W High
55.42
52W Low
23
Volume
50,229
Avg. Volume
-
Mkt Cap
1.92B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
2DecExpected
Q1 2026
Q2 2026
Next
-23.98
-16.16
-8.33
-0.51
Expected EPS
-0.51
Actual EPS
N/A
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Show more...
CEO
Benny Sorensen
Employees
59
Country
United States
ISIN
US4234941031
Listings
0 Comments
Share your thoughts
FAQ
What is Hemab Therapeutics stock price today?▼
The current price of COAG is $41.19 USD — it has decreased by -0.07% in the past 24 hours. Watch Hemab Therapeutics stock price performance more closely on the chart.
What is Hemab Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Hemab Therapeutics stocks are traded under the ticker COAG.
What is Hemab Therapeutics market cap?▼
Today Hemab Therapeutics has the market capitalization of 1.92B
When is the next Hemab Therapeutics earnings date?▼
Hemab Therapeutics is going to release the next earnings report on December 02, 2026.
What were Hemab Therapeutics earnings last quarter?▼
COAG earnings for the last quarter are -0.8 USD per share, whereas the estimation was -0.73 USD resulting in a -9.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Hemab Therapeutics have?▼
As of September 21, 2026, the company has 59 employees.
In which sector is Hemab Therapeutics located?▼
Hemab Therapeutics operates in the Health & Wellness sector.
When did Hemab Therapeutics complete a stock split?▼
Hemab Therapeutics has not had any recent stock splits.
Where is Hemab Therapeutics headquartered?▼
Hemab Therapeutics is headquartered in CAMBRIDGE, United States.